Cargando…

Comorbidities and mortality among patients with chronic obstructive pulmonary disease

INTRODUCTION: Comorbidities are common in patients with chronic obstructive pulmonary disease (COPD). Estimates of prevalence, incidence and prognostic impact of comorbidities provide foundational knowledge of COPD epidemiology. We examined the prevalence, incidence and prognostic impact of 21 comor...

Descripción completa

Detalles Bibliográficos
Autores principales: Skajaa, Nils, Laugesen, Kristina, Horváth-Puhó, Erzsébet, Sørensen, Henrik Toft
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551998/
https://www.ncbi.nlm.nih.gov/pubmed/37797964
http://dx.doi.org/10.1136/bmjresp-2023-001798
_version_ 1785115884653641728
author Skajaa, Nils
Laugesen, Kristina
Horváth-Puhó, Erzsébet
Sørensen, Henrik Toft
author_facet Skajaa, Nils
Laugesen, Kristina
Horváth-Puhó, Erzsébet
Sørensen, Henrik Toft
author_sort Skajaa, Nils
collection PubMed
description INTRODUCTION: Comorbidities are common in patients with chronic obstructive pulmonary disease (COPD). Estimates of prevalence, incidence and prognostic impact of comorbidities provide foundational knowledge of COPD epidemiology. We examined the prevalence, incidence and prognostic impact of 21 comorbidities among patients with COPD compared with the Danish general population. METHODS: We conducted a nationwide, population-based cohort study based on longitudinal Danish registry data, covering all Danish hospitals (2010–2021). The cohorts comprised 142 973 patients with a first-time hospital-based diagnosis of COPD and 428 917 age-matched and sex-matched comparators from the general population. During follow-up, we estimated the 5-year risk and risk difference, using competing risk methods when applicable. RESULTS: At time of diagnosis, the comorbidities with the highest prevalence were mood, stress-related or anxiety disorders (25.2% for patients with COPD vs 13.1% for comparators), osteoporosis/hip fractures (17.4% vs 9.9%), diabetes (15.6% vs 10.5%), peripheral arterial disease (13.5% vs 4.9%) and heart failure (13.3% vs 4.0%). During follow-up, the risk of most incident comorbidities was markedly elevated among patients with COPD. The five comorbidities associated with the highest 5-year absolute risk difference with respect to the risk in the general population were mood, stress-related or anxiety disorders (5.7%), osteoporosis/hip fractures (5.6%), heart failure (4.2%), smoking-related cancers (2.8%) and peripheral arterial disease (2.7%). The 5-year mortality risk was 43% vs 17.7%. Among patients with COPD, the 5-year mortality risk markedly increased with the number of comorbidities present. CONCLUSIONS: Our population-based findings underscore the importance of considering comorbidities in the management of COPD.
format Online
Article
Text
id pubmed-10551998
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-105519982023-10-06 Comorbidities and mortality among patients with chronic obstructive pulmonary disease Skajaa, Nils Laugesen, Kristina Horváth-Puhó, Erzsébet Sørensen, Henrik Toft BMJ Open Respir Res Chronic Obstructive Pulmonary Disease INTRODUCTION: Comorbidities are common in patients with chronic obstructive pulmonary disease (COPD). Estimates of prevalence, incidence and prognostic impact of comorbidities provide foundational knowledge of COPD epidemiology. We examined the prevalence, incidence and prognostic impact of 21 comorbidities among patients with COPD compared with the Danish general population. METHODS: We conducted a nationwide, population-based cohort study based on longitudinal Danish registry data, covering all Danish hospitals (2010–2021). The cohorts comprised 142 973 patients with a first-time hospital-based diagnosis of COPD and 428 917 age-matched and sex-matched comparators from the general population. During follow-up, we estimated the 5-year risk and risk difference, using competing risk methods when applicable. RESULTS: At time of diagnosis, the comorbidities with the highest prevalence were mood, stress-related or anxiety disorders (25.2% for patients with COPD vs 13.1% for comparators), osteoporosis/hip fractures (17.4% vs 9.9%), diabetes (15.6% vs 10.5%), peripheral arterial disease (13.5% vs 4.9%) and heart failure (13.3% vs 4.0%). During follow-up, the risk of most incident comorbidities was markedly elevated among patients with COPD. The five comorbidities associated with the highest 5-year absolute risk difference with respect to the risk in the general population were mood, stress-related or anxiety disorders (5.7%), osteoporosis/hip fractures (5.6%), heart failure (4.2%), smoking-related cancers (2.8%) and peripheral arterial disease (2.7%). The 5-year mortality risk was 43% vs 17.7%. Among patients with COPD, the 5-year mortality risk markedly increased with the number of comorbidities present. CONCLUSIONS: Our population-based findings underscore the importance of considering comorbidities in the management of COPD. BMJ Publishing Group 2023-10-04 /pmc/articles/PMC10551998/ /pubmed/37797964 http://dx.doi.org/10.1136/bmjresp-2023-001798 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Chronic Obstructive Pulmonary Disease
Skajaa, Nils
Laugesen, Kristina
Horváth-Puhó, Erzsébet
Sørensen, Henrik Toft
Comorbidities and mortality among patients with chronic obstructive pulmonary disease
title Comorbidities and mortality among patients with chronic obstructive pulmonary disease
title_full Comorbidities and mortality among patients with chronic obstructive pulmonary disease
title_fullStr Comorbidities and mortality among patients with chronic obstructive pulmonary disease
title_full_unstemmed Comorbidities and mortality among patients with chronic obstructive pulmonary disease
title_short Comorbidities and mortality among patients with chronic obstructive pulmonary disease
title_sort comorbidities and mortality among patients with chronic obstructive pulmonary disease
topic Chronic Obstructive Pulmonary Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551998/
https://www.ncbi.nlm.nih.gov/pubmed/37797964
http://dx.doi.org/10.1136/bmjresp-2023-001798
work_keys_str_mv AT skajaanils comorbiditiesandmortalityamongpatientswithchronicobstructivepulmonarydisease
AT laugesenkristina comorbiditiesandmortalityamongpatientswithchronicobstructivepulmonarydisease
AT horvathpuhoerzsebet comorbiditiesandmortalityamongpatientswithchronicobstructivepulmonarydisease
AT sørensenhenriktoft comorbiditiesandmortalityamongpatientswithchronicobstructivepulmonarydisease